Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 3 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 6 | 1 |
| 2 Introduction | 7 | 2 |
| 2.1 GBI Research Report Guidance | 8 | 1 |
| 3 Background: | 9 | 2 |
| 3.1 Major Services under Pharmaceutical Analytical Services | 10 | 1 |
| 3.1.1 Impurity Profile | 10 | 1 |
| 3.1.2 Analytical Method Development and Validations | 10 | 1 |
| 3.1.3 Particle Size Distribution | 10 | 1 |
| 4 Pharmaceutical Drug Discovery Outsourcing Market: Market Characterization | 11 | 5 |
| 4.1 Market Share and Market Size | 11 | 1 |
| 4.2 Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2004-2009 | 11 | 1 |
| 4.3 Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2009-2016 | 12 | 2 |
| 4.4 Forces that Drive Drug Discovery in India and China | 14 | 1 |
| 4.4.1 Declining R&D Productivity, Especially for Big Pharma | 14 | 2 |
| 5 Outsourcing Plan for Pharmaceutical Companies | 16 | 8 |
| 5.1 Why India and China? | 18 | 1 |
| 5.1.1 Availability of Skilled Manpower | 18 | 1 |
| 5.1.2 Improved IP Protection in India and China | 19 | 1 |
| 5.1.3 Government Support for Drug Discovery Development | 20 | 1 |
| 5.1.3.1 Hutchison MediPharma with Merck KGaA and Eli Lilly &Co | 20 | 1 |
| 5.1.3.2 Advinus Therapeutics with Ortho-McNeil-Janssen Pharmaceutical Inc, Genzyme Corporation and Merck &Co | 21 | 1 |
| 5.1.3.3 Ranbaxy with Merck &Co and GlaxoSmithKline | 21 | 1 |
| 5.1.4 SWOT Analysis of the Drug Discovery Industry in India | 22 | 1 |
| 5.1.5 Conclusion | 23 | 1 |
| 6 IP Protection in India and China Improved IP Protection to Encourage Innovation | 24 | 5 |
| Patent Act 2005 First Step towards Improving IP Protection | 25 | 1 |
| 6.2 IPR Enforcement Rules, 2007 | 26 | 1 |
| 6.3 Trademarks Bill 2007 | 26 | 1 |
| 6.4 Drugs and Cosmetics Act (Amendment) 2008 | 27 | 1 |
| 6.5 EIPR (Enforcers of Intellectual Property Rights) Ensuring IPR Laws Implementation in India | 27 | 2 |
| 7 Government and Regulatory Support in India Strong Support to Research Institutes and Small Companies | 29 | 4 |
| 7.1 Government/Regulatory Support for Drug Discovery in India | 29 | 1 |
| 7.1.1 Open Source Drug Discovery | 29 | 1 |
| 7.1.2 Drug Development Promotion Board: Encouraging a PPP Model for Drug Discovery and Development | 30 | 1 |
| 7.1.3 Technology Development Board: Supporting Technology Oriented Projects | 31 | 1 |
| 7.1.4 NMITLI (New Millennium Indian Technology Leadership Initiative) Scheme | 32 | 1 |
| 8 Pharmaceutical Analytical Services Outsourcing Market, Market Dynamics | 33 | 2 |
| 8.1 Pharmaceutical Analytical Services Outsourcing Market, Market Trends | 33 | 1 |
| 8.1.1 Pricing Pressures Driving Outsourcing of Pharmaceutical Analytical Work to Low Cost Destinations | 33 | 1 |
| 8.1.2 Flexibility Offered by Companies in Terms of Resource and Manpower Allocation Contributing Towards Increased Outsourcing | 33 | 1 |
| 8.1.3 Shared Risk Concept Encourages Greater Outsourcing of Drug Development | 33 | 1 |
| 8.2 Pharmaceutical Analytical Services Outsourcing Market, Market Drivers | 33 | 1 |
| Lower Cost is a Key Driver towards Chemistry Outsourcing to Asian CROs | 33 | 1 |
| 8.2.2 Demand for Shorter Research Cycle Driving Outsourcing of Chemistry Services | 34 | 1 |
| 8.3 Pharmaceutical Analytical Services Outsourcing Market, Market Restraints | 34 | 1 |
| 8.3.1 Intellectual Property and Legal Landscape is a Key Restraint in the Growth of Outsourcing of Pharmaceutical Analytical Services to Asian Countries | 34 | 1 |
| 9 Market Opportunity and Risk Assesment | 35 | 1 |
| 10 Future Outlook | 36 | 2 |
| 11 Major Indian Drug Discovery Companies Different Business Models to Provide Similar Services | 38 | 13 |
| 11.1 Indian Drug Discovery Business Model R&D Hive-off for Better Services and Risk Reduction | 38 | 1 |
| 11.2 Jubilant Organosys Jubilant Biosys | 39 | 1 |
| 11.2.1 About Jubilant Organosys | 39 | 1 |
| 11.2.2 Major Drug Discovery Deals | 40 | 1 |
| 11.3 Dr. Reddy s Aurigene | 41 | 1 |
| 11.3.1 About Dr. Reddy s | 41 | 1 |
| 11.3.2 Aurigene | 41 | 1 |
| 11.3.3 Major Drug Discovery Deals | 42 | 1 |
| 11.4 Biocon s Syngene | 43 | 1 |
| 11.4.1 About Biocon | 43 | 1 |
| 11.4.2 Syngene | 43 | 1 |
| 11.4.3 Major Drug Discovery Deals | 44 | 1 |
| 11.5 GVK BIO | 45 | 1 |
| 11.5.1 Business Description | 45 | 1 |
| 11.5.2 Major Drug Discovery Deals | 46 | 1 |
| 11.6 Advinus Therapeutics | 47 | 1 |
| 11.6.1 Business Description | 47 | 1 |
| 11.6.2 Major Drug Discovery Deals | 48 | 1 |
| 11.7 Sipra Labs | 49 | 1 |
| 11.7.1 Business Description | 49 | 1 |
| 11.8 Sai Advantium | 50 | 1 |
| 11.8.1 Business Description | 50 | 1 |
| 12 Deals Analysis Equal Thrust From Big Pharma and Mid-Size Pharma | 51 | 6 |
| 12.1 Number of Discovery Research Deals Increased Activity by Big and Mid-size Pharma | 51 | 1 |
| 12.2 Deals by Major Therapeutic Area Oncology and Metabolic Disorders | 52 | 1 |
| 12.3 Deals by Client Type Mid-size Pharma Deals Rising in India and China | 53 | 2 |
| 12.4 Major Drug Discovery Deals | 55 | 1 |
| 12.4.1 Amgen with Jubilant Biosys: Supporting Early Stage Preclinical Development Effort to Provide Cost-Effective Drugs | 55 | 1 |
| 12.4.2 Bristol-Myers Squibb with Syngene: Dedicated Research Facility for Discovery and Early Drug Development | 55 | 1 |
| 12.4.3 Novartis with Aurigene: Generating Pre-clinical Candidates for Oncology-focused Program | 55 | 1 |
| 12.4.4 Merck &Co with Advinus Therapeutics: To Develop Clinically Validated Drug Candidates for Metabolic Disorders | 55 | 1 |
| 12.5 Conclusion | 56 | 1 |
| 13 Future Challenges Financial and Intellectual Obstacles to Impede the Future Growth | 57 | 3 |
| 13.1 Financial Problems will Make it Difficult to Sustain the Growth | 57 | 1 |
| 13.2 Talent Shortage in Early Stage Chemistry and Biology | 57 | 1 |
| 13.3 Competition from Europe as an Alternative Discovery Research Destination | 58 | 1 |
| 13.4 Conclusion | 59 | 1 |
| 14 Key Takeaway | 60 | 1 |
| 15 Appendix | 61 | 5 |
| 15.1 Definitions | 61 | 1 |
| 15.2 Market Definitions | 61 | 1 |
| 15.3 Acronyms | 61 | 3 |
| 15.4 Research Methodology | 64 | 2 |
| 15.4.1 Secondary Research | 64 | 1 |
| 15.4.2 Primary Research | 64 | 1 |
| 15.4.3 Models | 65 | 1 |
| 15.4.4 Forecasts | 65 | 1 |
| 15.4.5 Expert Panels | 65 | 1 |
| 15.5 Contact Us | 65 | 1 |
| 15.6 Disclaimer | 65 | 1 |